Late-Onset Neutropenia in a Single-Center, Retrospective Cohort of Central Nervous System Autoimmunity Patients Treated with Anti-CD20
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Late-onset neutropenia (LON) is an infrequently reported, unpredictable side effect of anti-CD20 therapy, with incidence varying by agent, diagnosis, and screening protocol.
Objective
The primary objective of this cross-sectional, retrospective study was to estimate the proportion of patients who developed LON over 13 months (April 2023–April 2024).
Methods
Consecutive adult patients diagnosed with central nervous system (CNS) autoimmunity who received at least one rituximab(RTX) or ocrelizumab(OCR) infusion between January 2016 and March 2024 were included; patients who switched to another immunotherapy, had no post-treatment blood draw, or had unverifiable infusion records were excluded. LON events were assessed using all post-treatment CBCD blood draws during this period.
Results
A total of 171 patients were enrolled: 141 received rituximab and 30 received ocrelizumab. A total of 319 post-treatment blood tests were performed. Sixteen patients (16/171) had neutropenia (9.4%, 95% CI 5.8–14.7): 12 on rituximab (8.5%) and 4 on ocrelizumab (13.3%; p=0.487). LON occurred at a median of 158 days (130–188) since the last infusion. All patients were asymptomatic, mostly had Grade 1 neutropenia (15/16, 93.8%). BMI (22.2 vs. 27.5 kg/mš, p=0.001) and prior natalizumab exposure (37.5% vs. 14.2%, p=0.023) were significantly different between neutropenic and non-neutropenic patients.
Conclusion
The proportion of patients with LON in this cohort was higher than most previously reported, with all cases asymptomatic. Lower BMI and prior natalizumab exposure emerged as potential risk factors warranting further investigation. Larger, prospective studies with standardized surveillance are needed to establish the true frequency and risk factors.
